TXG
$18.39+0.01 (+0.05%)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.
Recent News
3 Reasons to Sell TXG and 1 Stock to Buy Instead
10x Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% and now trades at $18.24. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
10x Genomics CRISPR Brain Atlas Collaboration And What It Means For Investors
10x Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single cell and spatial technologies with advanced AI and high performance computing to map gene function in the brain. The project is presented as a new resource for neuroscience and therapeutic research focused on brain function and disease. For readers tracking 10x Genomics, this collaboration...
Stock Market Today, March 16: Nasdaq Gains 1% Stocks on Easing Oil Prices and AI Optimism
On March 16, 2026, cooling oil prices meant markets erased some of last week's losses today, though geopolitical risks lingered.
1 Cash-Producing Stock with Competitive Advantages and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 3.8%, nearly mirrorring the S&P 500.